Literature DB >> 4049032

Prolonged hospitalization because of inappropriate delay of warfarin therapy in deep venous thrombosis.

T U Westblom, R D Marienfeld.   

Abstract

Current anticoagulation practices of physicians in an academic medical center were examined by retrospective review of records of 26 patients admitted for uncomplicated deep venous thrombosis (DVT) between 1978 and 1982. Patients received intravenous heparin for an average of 11.5 +/- 2.8 days. Warfarin therapy was started on day 8.3 +/- 3.1 and therapeutic oral anticoagulation was achieved by day 14.5 +/- 4.5. Total hospital stay averaged 16.8 +/- 5.1 days. No patient received concurrent initiation of heparin and warfarin therapy and only two patients received warfarin before day 5. These findings are in contrast to anticoagulation practices in Great Britain and Scandinavia where concurrent initiation of heparin and warfarin has been common practice for many years. Such a regimen is safe and usually requires fewer days of hospitalization for DVT. We conclude that failure to start warfarin therapy on the first hospital day resulted in a costly and unnecessarily prolonged hospital stay.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4049032     DOI: 10.1097/00007611-198510000-00005

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

Review 1.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

2.  Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study.

Authors:  Charlène Insam; Marie Méan; Andreas Limacher; Anne Angelillo-Scherrer; Markus Aschwanden; Martin Banyai; Juerg-Hans Beer; Henri Bounameaux; Michael Egloff; Beat Frauchiger; Marc Husmann; Nils Kucher; Bernhard Lämmle; Christian Matter; Joseph Osterwalder; Marc Righini; Daniel Staub; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.